Analysis of aggregation profile of glucagon using SEC-HPLC and FFF-MALS methods
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0304086 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Zhongli Bao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, California, California, United States of America. Hauptthemen laut MEDLINE: Glucagon, Chromatography, Gel, Protein Aggregates. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Amphastar Pharmaceuticals, Inc..
Abstract (Originalsprache)
Recently, the first generic glucagon for injection was approved for the treatment of severe hypoglycemia. Unlike its brand name recombinant glucagon, the generic glucagon is synthetic. Since glucagon has a high propensity to form aggregates in solution, it is essential to assess the aggregation profile of the synthetic glucagon compared to the recombinant glucagon. In this study, two robust separation methods, size-exclusion chromatography (SEC-HPLC) and field-flow fractionation coupled with a multi-angle light scattering detector (FFF-MALS), were employed to characterize generic and brand glucagon aggregation in six lots (three newly released, three expired). The presence of aggregation in samples was determined from the generated chromatograms and analyzed. The study showed that both products have comparable aggregation profiles. The SEC-HPLC demonstrated that in both glucagon versions, the expired lots had a higher percentage of dimers than the newly released lots, but even at expiration, the amount was negligible (∼0.1%). The FFF-MALS method did not detect any dimers or higher molecular weight aggregates. Further evaluation of the detection limit found that FFF-MALS was unable to detect aggregates at amounts lower than 0.5% of total glucagon. The negligible amounts of dimer detected in the generic and brand glucagon indicate that both versions are physically stable and are not prone to aggregation under clinically relevant conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, California, California, United States of America.
ORCID-Profile: Jack Yongfeng Zhang
Förderung
- Amphastar Pharmaceuticals, Inc.
Zitieren
APA
Bao, Z., Cheng, Y. C., Luo, M. Z., & Zhang, J. Y. (2024). Analysis of aggregation profile of glucagon using SEC-HPLC and FFF-MALS methods. PLOS ONE. https://doi.org/10.1371/journal.pone.0304086
Vancouver
Bao Z, Cheng YC, Luo MZ, Zhang JY. Analysis of aggregation profile of glucagon using SEC-HPLC and FFF-MALS methods. PLOS ONE. 2024. doi:10.1371/journal.pone.0304086
BibTeX
@article{Bao2024,
author = {Bao, Zhongli and Cheng, Ya-Chi and Luo, Mary Ziping and Zhang, Jack Yongfeng},
title = {Analysis of aggregation profile of glucagon using SEC-HPLC and FFF-MALS methods},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0304086}
}
EUVIMED